Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

被引:14
|
作者
Topp, Max S. [1 ]
Stein, Anthony S. [2 ]
Goekbuget, Nicola [3 ]
Horst, Heinz-August [4 ]
Boissel, Nicolas [5 ]
Martinelli, Giovanni [6 ]
Kantarjian, Hagop [7 ]
Brueggemann, Monika [8 ]
Chen, Yuqi [9 ]
Zugmaier, Gerhard [10 ]
机构
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] City Hope Med Ctr, Gehr Leukemia Ctr, Duarte, CA USA
[3] Univ Klinikum, Med Klin Hamatol Onkol Rheumatol Infektiol 3, Frankfurt, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Innere Med 2, Kiel, Germany
[5] Hop St Louis, Unite Hematol Adolescents & Jeunes Adultes, Paris, France
[6] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Sci Directorate, Meldola, FC, Italy
[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[8] Univ Klinikum Schleswig Holstein, Sekt Hamatol Spezialdiagnost, Klin Innere Med 2, Kiel, Germany
[9] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[10] Amgen Res Munich GmbH, Global Dev, Munich, Germany
来源
CANCER MEDICINE | 2021年 / 10卷 / 08期
关键词
acute lymphoblastic leukemia; BiTE® blinatumomab; salvage; stem cell transplant;
D O I
10.1002/cam4.3731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Blinatumomab is a BiTE(R) immuno-oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in patients with r/r BCP ALL. Patient-level pooled data were used for this analysis. In total, 532 adults with r/r BCP ALL treated with blinatumomab were included (first salvage, n = 165; second or later salvage, n = 367). Compared with patients who received blinatumomab as second or later salvage, those who received blinatumomab as first salvage had a longer median overall survival (OS; 10.4 vs. 5.7 months; HR, 1.58; 95% CI, 1.26-1.97; P < .001) and relapse-free survival (10.1 vs. 7.3 months; HR, 1.38; 95% CI, 0.98-1.93; P = .061), and higher rates of remission (n = 89 [54%] vs. n = 150 [41%]; odds ratio, 0.59; 95% CI, 0.41-0.85; P = .005), minimal residual disease response (n = 68 [41%] vs. n = 118 [32%]), and allogeneic hematopoietic stem cell transplant (alloHSCT) realization (n = 60 [36%] vs. n = 88 [24%]), and alloHSCT in continuous remission (n = 33 [20%] vs. n = 52 (14%]). In a subgroup analysis, there was no apparent effect of prior alloHSCT on median OS in either salvage group. The safety profile of blinatumomab was generally similar between the groups; however, cytokine release syndrome, febrile neutropenia, and infection were more frequent with second or later salvage than with first salvage. In this pooled analysis, the logistic regression analyses indicated greater benefit with blinatumomab as first salvage than as second or later salvage, as evident by the longer median OS, longer median RFS, and higher rates of remission. Overall, blinatumomab was beneficial as first salvage and as second or later salvage, but the effects were favorable as first salvage. Aims Materials & Methods Results Discussion Conclusion
引用
收藏
页码:2601 / 2610
页数:10
相关论文
共 50 条
  • [21] A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Keizo Horibe
    Joan D. Morris
    Catherine A. Tuglus
    Cedric Dos Santos
    James Kalabus
    Abraham Anderson
    Hiroaki Goto
    Chitose Ogawa
    International Journal of Hematology, 2020, 112 : 223 - 233
  • [22] Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Salhotra, Amandeep
    Yang, Dongyun
    Mokhtari, Sally
    Al Malki, Monzr M.
    Ali, Haris
    Sandhu, Karamjeet S.
    Aribi, Ahmed
    Khaled, Samer
    Mei, Matthew
    Budde, Elizabeth
    Snyder, David
    Cao, Thai
    Spielberger, Ricardo
    Marcucci, Guido
    Pullarkat, Vinod
    Forman, Stephen J.
    Nakamura, Ryotaro
    Stein, Anthony
    Aldoss, Ibrahim
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (06) : 1084 - 1090
  • [23] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Dombret, Herve
    Bonifacio, Massimiliano
    Reichle, Albrecht
    Graux, Carlos
    Faul, Christoph
    Diedrich, Helmut
    Topp, Max S.
    Brueggemann, Monika
    Horst, Heinz-August
    Havelange, Violaine
    Stieglmaier, Julia
    Wessels, Hendrik
    Haddad, Vincent
    Benjamin, Jonathan E.
    Zugmaier, Gerhard
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2018, 131 (14) : 1522 - 1531
  • [24] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Delea, Thomas E.
    Zhang, Xinke
    Amdahl, Jordan
    Boyko, Diana
    Dirnberger, Franziska
    Campioni, Marco
    Cong, Ze
    PHARMACOECONOMICS, 2019, 37 (09) : 1177 - 1193
  • [25] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Thomas E. Delea
    Xinke Zhang
    Jordan Amdahl
    Diana Boyko
    Franziska Dirnberger
    Marco Campioni
    Ze Cong
    PharmacoEconomics, 2019, 37 : 1177 - 1193
  • [26] Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
    Franco Locatelli
    James A. Whitlock
    Christina Peters
    Christiane Chen-Santel
    Victoria Chia
    Robyn M. Dennis
    Kenneth M. Heym
    Aaron J. Katz
    Michael A. Kelsh
    Richard Sposto
    Huakang Tu
    Catherine A. Tuglus
    Anupam Verma
    Luciana Vinti
    Jennifer J. Wilkes
    Nathalya Zubarovskaja
    Gerhard Zugmaier
    Arend von Stackelberg
    Weili Sun
    Leukemia, 2020, 34 : 2473 - 2478
  • [27] Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
    Locatelli, Franco
    Whitlock, James A.
    Peters, Christina
    Chen-Santel, Christiane
    Chia, Victoria
    Dennis, Robyn M.
    Heym, Kenneth M.
    Katz, Aaron J.
    Kelsh, Michael A.
    Sposto, Richard
    Tu, Huakang
    Tuglus, Catherine A.
    Verma, Anupam
    Vinti, Luciana
    Wilkes, Jennifer J.
    Zubarovskaja, Nathalya
    Zugmaier, Gerhard
    von Stackelberg, Arend
    Sun, Weili
    LEUKEMIA, 2020, 34 (09) : 2473 - 2478
  • [28] Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
    Badar, Talha
    Szabo, Aniko
    Dinner, Shira
    Liedtke, Michaela
    Burkart, Madelyn
    Shallis, Rory M.
    Yurkiewicz, Ilana R.
    Kuo, Eric
    Khan, Muhammad Ali
    Balasubramanian, Suresh
    Yang, Jay
    Hefazi, Mehrdad
    Podoltsev, Nikolai
    Patel, Anand
    Curran, Emily
    Wang, Amy
    Arslan, Shukaib
    Aldoss, Ibrahim
    Siebenaller, Caitlin
    Mattison, Ryan J.
    Litzow, Mark R.
    Wadleigh, Martha
    Advani, Anjali S.
    Atallah, Ehab
    CANCER, 2021, 127 (07) : 1039 - 1048
  • [29] Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: Compassionate Access
    Radhakrishnan, Vivek S.
    Modak, Ketan
    Bhave, Saurabh J.
    Kumar, Jeevan
    Roychowdhury, Mita
    Ghosh, Manik
    Parihar, Mayur
    Arora, Neeraj
    Mishra, Deepak K.
    Nair, Reena
    Chandy, Mammen
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (02) : 199 - 203
  • [30] T-CELL RECEPTOR. REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA ON BLINATUMOMAB TREATMENT
    Knecht, H.
    Kotrova, M.
    Reigl, T.
    Krejci, A.
    Herrmann, D.
    Schwarz, M.
    Bystry, V.
    Darzentas, N.
    Bruegemann, M.
    HAEMATOLOGICA, 2017, 102 : 329 - 330